Close Menu

Tekmira

Tekmira Pharmaceuticals last week announced that it has acquired a worldwide, non-exclusive license to Marina Biotech's unlocked nucleobase analog technology, which is used to design RNAi payloads.

Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.

Emboldened by a $65 million payout from Alnylam Pharmaceuticals as part of a litigation settlement, Tekmira Pharmaceuticals this week offered a pipeline update that includes the “aggressive advancement” of a number of drug candidates.

Alnylam Pharmaceuticals this week updated its financial guidance to include the impact of its payout to Tekmira Pharmaceuticals as part of the companies' litigation settlement deal.

Alnylam Pharmaceuticals this week disclosed that a jury trial for its trade secret litigation with Tekmira Pharmaceuticals is expected to begin Nov. 14.

Title: Genetic Inhibition of Double-Stranded RNA
Patent Number: 8,283,329
Filed: Sept. 28, 2007
Lead Inventor: Andrew Fire, Carnegie Institution

Tekmira Pharmaceuticals this week announced that the US Department of Defense has decided to continue its contract with the company to develop an RNAi-based treatment for Ebola virus infection.

Tekmira Pharmaceuticals said last week that the US Department of Defense has extended the temporary stop-work order it recently imposed on its partnership with the company to develop an RNAi-based treatment for Ebola virus infection.

Tekmira Pharmaceuticals this week released interim results from an ongoing phase I trial of its siRNA-based cancer treatment TKM-PLK1, which showed the drug to be well tolerated despite an “aggressive” dosing regimen, with some signs of clinical activity.

Title: Triggered RNAi
Patent Number: 8,241,854
Filed: May 22, 2009
Lead Inventor: Peng Yin, California Institute of Technology

Pages

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.